A Comparison Between Glargine and Detemir Insulin in Type 2 Diabetes

• Status: Completed
• Trial end date: 2007-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study that when studies using our method of dosing adjustments driven by continuous glucose monitoring and because of the less variable glycemic effect of insulin detemir, insulin detemir treated subjects will spend a significantly greater time in the glucose target range than insulin glargine.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Diabetes Care Center
• Collaborator: Novo Nordisk A/S
• Treatments: Insulin; Insulin Glargine

Criteria

Inclusion Criteria:

• Type 2 Diabetes

• Currently on a basal insulin, that is, NPH, glargine or detemir

• Capable of self monitoring glucose >4/day

• Previously complaint with clinical recommendations

• Subject may be on oral antiglycemic medications but no change in treatment is permitted during study.

Exclusion Criteria:

• Hb A1c >9.0%

• Urinary ketosis

• Currently or expected alteration in insulin sensitivity such as major surgery, infection, renal failure (creatine >1.5 mg/dL) glucocorticoid treatment, recent (within 2 weeks) serious hypoglycaemic episode (requires assistance of another)

• Currently participating in another clinical trial

• Known or suspected allergy to insulin glargine or detemir

• Using other insulins, such as, bolus insulin or premixed insulin

• Sight or hearing impaired

• Pregnancy oor nursing of the intention of becoming pregnant or not using adequate contraceptive measures.